• BGJ398 (NVP-BGJ398): Precision FGFR Inhibition in Oncology R

  2026-07-17

  Explore how BGJ398 (NVP-BGJ398) redefines FGFR-driven malignancies research through selective inhibition and advanced mechanistic insight. This article uniquely bridges molecular pharmacology and developmental biology, providing evidence-based guidance for oncology research.

• Recombinant Human Oncostatin M: Precision for Cytokine Assay

  2026-07-17

  Recombinant Human Oncostatin M (E.coli, Tag Free, Lyophilized) from APExBIO delivers ultra-high purity and bioactivity, enabling reproducible cytokine stimulation and proliferation assays in fibroblast, smooth muscle, and tumor cell research. Optimized protocol parameters and robust troubleshooting guidance help researchers achieve reliable, high-sensitivity results across diverse cell models.

• Novel Platinum Complexes Trigger Rapid ROS-Mediated Cancer C

  2026-07-16

  The referenced study introduces a platinum-based therapeutic, carrier-platin, that induces a rapid and unique form of cancer cell death by generating an intracellular 'ROS storm.' Distinct from conventional platinum drugs, this nanomedicine bypasses DNA damage mechanisms and shows high efficacy—even against multidrug-resistant cancer models—while minimizing systemic toxicity.

• NUAK1 Inhibition Lowers Pathogenic Tau in Alzheimer’s Models

  2026-07-16

  Taylor et al. (2023) demonstrate that phosphorylation of tau at serine 356—a modification implicated in Alzheimer’s disease—can be selectively reduced by pharmacological NUAK1 inhibition using WZ4003. Their ex vivo studies in mouse and human brain tissues reveal differential responses, underscoring both the therapeutic potential and context-specific outcomes of targeting NUAK1 in neurodegeneration.

• HRP Goat Anti-Mouse IgG (H+L) Antibody: Protocols & Troubles

  2026-07-15

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU: K1221) addresses the need for reliable, sensitive detection of mouse primary antibodies in immunoassays such as Western blot, ELISA, IHC, and ICC. This affinity-purified, HRP-conjugated secondary antibody is optimized for signal amplification in mouse IgG detection workflows. It is not suitable for direct detection of non-mouse IgG or for use in assays incompatible with HRP-based detection methods.

• Potent Pyrimidine Inhibitors of TSSK2: Advances in Contracep

  2026-07-15

  This study identifies and characterizes the first sub-100 nM pyrimidine and pyrrolopyrimidine inhibitors of TSSK2, a kinase essential for male fertility. The findings establish new chemical scaffolds and robust screening methodologies, underpinning future structure-based selective inhibitor discovery for reversible male contraception.

• Nullscript: HDAC Inhibition Beyond Transcription—Epigenetic

  2026-07-14

  Explore how Nullscript, a distinctive histone deacetylase inhibitor, enables unprecedented precision in dissecting HDAC-dependent mechanisms—without confounding transcriptional activation. This article reveals new paradigm-shifting applications for Nullscript in cardiac and neurodegenerative research.

• Modeling Human Pacemaker Maturation with SAN-Plexus Assemblo

  2026-07-14

  This study introduces a human stem cell-derived assembloid system combining sinoatrial node and cardiac plexus organoids to model the neural regulation of pacemaker cell maturation. The platform enables mechanistic dissection of neuron-to-pacemaker signaling pathways, providing a new foundation for research into cardiac conduction disorders and autonomic regulation.

• Cyclophosphamide: Protocols and Innovations in Cancer Resear

  2026-07-13

  Cyclophosphamide stands as a gold-standard alkylating chemotherapeutic agent, enabling precise apoptosis induction and immune modulation in both oncology and autoimmune research. This guide translates cutting-edge protocol enhancements, troubleshooting strategies, and comparative insights into actionable workflows for maximizing scientific impact and experimental reproducibility.

• Nullscript: Precision Histone Deacetylase Inhibitor Workflow

  2026-07-13

  Nullscript delivers targeted HDAC inhibition for dissecting cardiac injury, neurodegeneration, and cancer pathways—while minimizing off-target transcriptional effects. Its inactivity in transcriptional facilitation and robust in vivo cardioprotection distinguish Nullscript as an indispensable tool for next-generation epigenetic research.

• Distinct Death Pathways in ALL Cells After Microtubule Disru

  2026-07-12

  This study demonstrates that primary acute lymphoblastic leukemia (ALL) cells undergo cell death via different molecular pathways depending on whether microtubule depolymerization occurs in G1 or M phase. These findings challenge the traditional focus on mitotic apoptosis in cancer therapy and highlight the importance of cell cycle context in the response to microtubule-targeting agents.

• 4-Phenylbutyric Acid in ER Stress Pathways: Mechanistic Insi

  2026-07-10

  Discover how 4-Phenylbutyric acid serves as a chemical chaperone for ER stress alleviation, with a focus on mechanistic details and assay design. Unique to this article: a deep dive into molecular pathways, PFOS-induced stress models, and practical protocols for advanced research.

• Octenidine Dihydrochloride: Advanced Antiseptic Workflows in

  2026-07-09

  Octenidine dihydrochloride sets a new benchmark for research-grade antiseptic workflows, offering robust microbial membrane disruption and high solubility for precise assay design. This guide unpacks protocols, troubleshooting, and recent gemini QAC innovations, empowering researchers to optimize antimicrobial studies with confidence.

• Oteseconazole (VT-1161): Optimizing Antifungal Assays for Ca

  2026-07-09

  Oteseconazole (VT-1161) is redefining antifungal research workflows by enabling precise, selective inhibition of Candida growth—even in fluconazole-resistant strains. This guide delivers actionable protocols, troubleshooting strategies, and insights from recent medicinal chemistry breakthroughs to boost reproducibility and impact in your laboratory.

• Low-Cost Microfluidic Mixers for Lipid Nanoparticle mRNA For

  2026-07-08

  Forrester et al. critically evaluate whether affordable microfluidic mixers can produce lipid nanoparticles (LNPs) for mRNA delivery with comparable quality to more advanced or manual methods. Their findings support the use of low-cost mixer designs for small-scale and high-throughput LNP research, ensuring accessibility without sacrificing encapsulation efficiency or expression outcomes.

451 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page